The epigenetically active small chemical N-methyl pyrrolidone (NMP) prevents estrogen depletion induced osteoporosis

Metadata Label Value
Author(s) Gjoksi, Bebeka, Ghayor, Chafik, Siegenthaler, Barbara M., Ruangsawasdi, Nisarat, Zenobi-Wong, Marcy, Weber, Franz E.
Publication Type Journal Items, Publication Status: Published
Full Text Search SFX for a Full-Text version of this document
Import to Mendeley Log in to provide feedback

Detailed Information

Metadata Field Content
Title The epigenetically active small chemical N-methyl pyrrolidone (NMP) prevents estrogen depletion induced osteoporosis
Author(s) Gjoksi, Bebeka
Ghayor, Chafik
Siegenthaler, Barbara M.
Ruangsawasdi, Nisarat
Zenobi-Wong, Marcy
Weber, Franz E.
Journal or Series Title Bone
Volume Number 78
Start Page 114
End Page 121
ISSN 8756-3282
1873-2763
Publisher Elsevier
Publication Place Amsterdam
Publication Date 2015-09
Keyword(s) Epigenetic
NMP
Osteoporosis
Bromodomain
BET proteins
Estrogen deficiency
Abstract Currently, there are several treatments for osteoporosis however; they all display some sort of limitation and/or side effects making the need for new treatments imperative. We have previously demonstrated that NMP is a bioactive drug which enhances bone regeneration in vivo and acts as an enhancer of bone morphogenetic protein (BMP) in vitro. NMP also inhibits osteoclast differentiation and attenuates bone resorption.

In the present study, we tested NMP as a bromodomain inhibitor and for osteoporosis prevention on ovariectomized (OVX) induced rats while treated systemically with NMP. Female Sprague–Dawley rats were ovariectomized and weekly NMP treatment was administrated 1 week after surgery for 15 weeks. Bone parameters and related serum biomarkers were analyzed. 15 weeks of NMP treatment decreased ovariectomy-induced gained weight in average by 43% and improved bone mineral density (BMD) and bone volume over total volume (BV/TV) in rat femur on average by 25% and 41% respectively. Moreover, mineral apposition rate and bone biomarkers of bone turnover in the treatment group were at similar levels with those of the Sham group.

Due to the function of NMP as a low affinity bromodomain inhibitor and its mechanism of action involving osteoblasts/osteoclasts balance and inhibitory effect on inflammatory cytokines, NMP is a promising therapeutic compound for the prevention of osteoporosis.
DOI 10.1016/j.bone.2015.05.004
Additional Notes Received 29 January 2015, Revised 20 April 2015, Accepted 2 May 2015, Published online 7 May 2015
Document Type Article
Publication Status Published
Language English
Assigned Organisational Unit(s) 03949
Organisational Unit(s)
NEBIS System Number 004142307
Source Database ID SCOPUS-84929305478
WOS-000356562000015
Description File Name MIME Type Size
No details could be found
There are no links available for this record.
This record has not been viewed during this period

@article{Gjks2015,
  author = "Gjoksi, Bebeka and Ghayor, Chafik and Siegenthaler, Barbara M. and Ruangsawasdi, Nisarat and Zenobi-Wong, Marcy and Weber, Franz E.",
  title = "{T}he epigenetically active small chemical {N}-methyl pyrrolidone ({N}{M}{P}) prevents estrogen depletion induced osteoporosis",
  journal = "Bone",
  year = 2015,
  volume = "78",
  pages = "114--121",
  month = sep,
}


E-Citations record created: Tue, 02 Jun 2015, 08:55:24 CET